We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

New Jersey joins wave of states proposing new rules for drug marketing and HCP interactions

11 September 2017

Health Alert

Drug manufacturers are once again facing new state limits on marketing and interactions with healthcare providers. Manufacturers should review the new laws and regulations carefully, consider how they might engage with the agencies interpreting the new limits, and begin preparing their own compliance efforts.

Read More: New Jersey Joins Wave of States Proposing New Rules for Drug Marketing and HCP Interactions


Loading data